A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2023-06-14
Target enrollment:
Participant gender:
Summary
Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a
twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.